BioRest

BioRest was an Israeli private biotechnology company focused on cardiovascular therapeutics and related uses of bisphosphonate-based drug formulations. Its best-known development program was liposomal alendronate for prevention of restenosis after coronary stenting, including the BLAST clinical study in patients with coronary artery stenosis. Patent records and secondary pipeline databases also associate the company with programs and intellectual property covering acute coronary syndromes and adjunctive uses of bisphosphonates in HIV/AIDS. Available business-registry sources indicate the company was voluntarily dissolved, so it does not appear to be an active operating biotech today. BioRest appears to have been an R&D-stage company centered on a drug-delivery platform rather than a diversified commercial pharmaceutical business.